Clinigence Holdings (NUTX) AI Stock Analysis

• Market Cap: $533.90M
• Dividend Yield: N/A
• Average Volume (3M): 198.95K
• Price to Earnings (P/E): 8.1
• Beta (1Y): 2.33
• Revenue Growth: 141.25%
• EPS Growth: N/A
• Country: US
• Employees: 800
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -5.43
• Shares Outstanding: 5,555,116
• 10 Day Avg. Volume: 154,139
• 30 Day Avg. Volume: 198,947
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 0.85
• Enterprise Value/Gross Profit: 1.73
• Enterprise Value/Ebitda: 2.47
• 1Y Price Target: $252.50
• Price Target Upside: 162.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 71 Outperform
• Price Target: $99.00 ▲(3.01% Upside)

NUTX demonstrates strong financial performance with notable revenue growth and profitability improvements. The stock's low P/E ratio suggests it is undervalued, offering potential for price appreciation. However, technical indicators present mixed signals, and concerns over financial leverage and reliance on arbitration revenue warrant cautious optimism.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability and market position.

Cash Flow Improvement

Improved cash flow supports operational flexibility and investment capacity, crucial for sustaining growth and navigating industry challenges.

Patient Volume Growth

Rising patient volumes reflect increased service adoption and market penetration, reinforcing the company's competitive position and revenue potential.

Negative Factors

Dependence on Arbitration Revenue

Heavy reliance on arbitration revenue introduces risk, as changes in regulatory or arbitration processes could significantly impact financial performance.

Delayed SEC Filings

Delayed filings can undermine investor confidence and indicate potential internal control issues, affecting the company's credibility and operational transparency.

Litigation and Regulatory Concerns

Ongoing litigation and regulatory scrutiny can lead to financial liabilities and distract management, impacting long-term strategic focus and resource allocation.

Clinigence Holdings Business Overview & Revenue Model

Company Description

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

How the Company Makes Money

Clinigence Holdings generates revenue primarily through the sale of its software solutions and services to healthcare providers, payers, and other stakeholders in the healthcare ecosystem. The company operates a subscription-based model, where customers pay recurring fees for access to its analytics platforms and telehealth services. Additionally, Clinigence may earn revenue through consulting services that help healthcare organizations optimize their operations and implement best practices in population health management. Strategic partnerships with healthcare providers, technology firms, and payer organizations also contribute to its revenue, enabling Clinigence to expand its market reach and enhance its service offerings.

Clinigence Holdings Financial Statement Overview

Summary

Clinigence Holdings demonstrates solid financial performance with notable revenue growth and profitability improvements. While the company shows efficient operational cash flow management, the balance sheet highlights increased leverage, which could pose future risks. Overall, the company is on a promising trajectory but should focus on stabilizing margins and managing leverage.

Income Statement

Clinigence Holdings shows strong revenue growth with a significant increase in total revenue on a TTM basis compared to previous periods. The gross profit margin has improved, indicating efficient cost management. Net profit margin is healthy, reflecting profitability. However, historical volatility in EBIT and EBITDA margins suggests potential instability.

Balance Sheet

The balance sheet reflects moderate financial leverage with a debt-to-equity ratio that has increased, potentially raising risk. However, the return on equity is robust, signaling effective use of equity. Equity ratio is reasonable, indicating a stable asset base but with room for improvement in reducing liabilities.

Cash Flow

Operating cash flow has improved significantly, supporting a positive free cash flow trajectory. The operating cash flow to net income ratio suggests strong operational efficiency. However, historical fluctuations in free cash flow growth underscore potential variability in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	624.28M	479.95M	247.65M	219.29M	331.53M	273.42M
Gross Profit	304.44M	196.26M	34.77M	13.45M	179.28M	271.60M
EBITDA	214.15M	148.65M	-14.58M	-393.96M	183.45M	-5.12M
Net Income	67.18M	52.18M	-45.79M	-424.78M	132.59M	105.97M
Balance Sheet
Total Assets	761.92M	655.32M	398.25M	431.75M	394.65M	308.55M
Cash, Cash Equivalents and Short-Term Investments	84.73M	43.58M	22.00M	34.26M	36.12M	25.51M
Total Debt	341.36M	340.30M	275.76M	267.20M	178.55M	150.12M
Total Liabilities	487.04M	453.43M	319.14M	311.42M	203.07M	161.19M
Stockholders Equity	197.11M	146.34M	61.45M	95.86M	114.65M	85.81M
Cash Flow
Free Cash Flow	69.43M	20.85M	-8.24M	35.97M	136.51M	25.48M
Operating Cash Flow	71.07M	23.15M	1.26M	50.61M	173.43M	86.67M
Investing Cash Flow	-2.00M	-2.67M	-11.24M	-4.34M	-36.98M	-61.19M
Financing Cash Flow	-11.41M	1.09M	-2.27M	-48.13M	-125.85M	-7.97M

Clinigence Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 96.11
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 96.11 is above the 20-day moving average (MA) of 88.90, above the 50-day MA of 93.57, and above the 200-day MA of 86.36, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 58.11 is Neutral, neither overbought nor oversold. The STOCH value of 80.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.

Clinigence Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	75 Outperform	868.49M	43.59	5.80%	0.41%	3.50%	13.99%
NUTX	71 Outperform	$533.90M	8.07	51.65%	―	141.25%	―
TXG	52 Neutral	1.62B	-18.57	-10.94%	―	2.02%	65.33%
DH	52 Neutral	612.67M	-1.62	-74.11%	―	-5.24%	23.59%
EVH	51 Neutral	1.01B	-5.35	-18.04%	―	-6.71%	-71.40%
HCAT	49 Neutral	207.60M	-1.95	-28.81%	―	5.55%	-0.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Clinigence Holdings Corporate Events

Clinigence Holdings Faces Derivative Action Lawsuit

On September 8, 2025, a derivative action was filed on behalf of Nutex Health Inc. in the U.S. District Court for the Southern District of Texas. The lawsuit names the company’s CEO, CFO, President, and current and former board members as defendants, alleging violations of the Securities Exchange Act, breaches of fiduciary duties, and other misconduct. The action seeks damages, restitution, and corporate governance reforms. Nutex Health is currently unable to predict the litigation’s outcome or its financial impact.

The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Nutex Health Appoints New Lead Independent Director

On September 2, 2025, Nutex Health, Inc. appointed Michael L. Reed as the Lead Independent Director of its Board of Directors. Reed, who has been a board member since April 2022, will facilitate communication between independent directors and the company’s management, reinforcing Nutex Health’s commitment to strong corporate governance and compliance with Nasdaq’s requirements. This move highlights the company’s dedication to maintaining robust corporate governance practices.

The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Nutex Health Faces Securities Class Action Lawsuit

On August 22, 2025, a securities class action complaint was filed against Nutex Health Inc. in the United States District Court for the Southern District of Texas. The complaint, which follows a recent short seller report, names the company’s top executives as defendants and alleges violations of the Securities Exchange Act of 1934. Nutex Health disputes the allegations and plans to defend itself vigorously, though an adverse ruling could significantly impact its financial position or operations.

The most recent analyst rating on (NUTX) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.

Clinigence Holdings Faces Nasdaq Delisting Notice

On August 20, 2025, Nutex Health Inc. received a notice from Nasdaq due to a delayed filing of its Quarterly Report, risking delisting if not resolved by October 20, 2025. The company is actively working to complete its financial filings. Additionally, Nutex Health disclosed that its previously issued financial statements should not be relied upon due to non-cash classification changes, which are being corrected. Despite these challenges, Nutex Health reported significant financial growth for the three and six months ended June 30, 2025, with total revenue increasing by over 200% compared to the previous year, driven by mature hospitals’ performance.

The most recent analyst rating on (NUTX) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.